Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection

Joseph Doggett, Kayode K. Ojo, Erkang Fan, Dustin J. Maly, Wesley C. Van Voorhis

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

Original languageEnglish (US)
Pages (from-to)3547-3549
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Toxoplasmosis
Toxoplasma
Phosphotransferases
Cryptosporidium
Plasmodium
Eye Diseases
Brain Diseases
Parasites
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection. / Doggett, Joseph; Ojo, Kayode K.; Fan, Erkang; Maly, Dustin J.; Van Voorhis, Wesley C.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 6, 2014, p. 3547-3549.

Research output: Contribution to journalArticle

Doggett, Joseph ; Ojo, Kayode K. ; Fan, Erkang ; Maly, Dustin J. ; Van Voorhis, Wesley C. / Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 6. pp. 3547-3549.
@article{8f20fc17f0b64d679858eed3e21586f5,
title = "Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection",
abstract = "Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.",
author = "Joseph Doggett and Ojo, {Kayode K.} and Erkang Fan and Maly, {Dustin J.} and {Van Voorhis}, {Wesley C.}",
year = "2014",
doi = "10.1128/AAC.01823-13",
language = "English (US)",
volume = "58",
pages = "3547--3549",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection

AU - Doggett, Joseph

AU - Ojo, Kayode K.

AU - Fan, Erkang

AU - Maly, Dustin J.

AU - Van Voorhis, Wesley C.

PY - 2014

Y1 - 2014

N2 - Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

AB - Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84901277406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901277406&partnerID=8YFLogxK

U2 - 10.1128/AAC.01823-13

DO - 10.1128/AAC.01823-13

M3 - Article

C2 - 24687502

AN - SCOPUS:84901277406

VL - 58

SP - 3547

EP - 3549

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -